SLC5A2 and type 1 diabetes mellitus: SGLT2 inhibitors provide insulin-independent glucose lowering effects by inhibiting glucose reabsorption in the proximal renal tubule, resulting in weight loss and A1C reduction in type 2 diabetes.26 However, the therapeutic use of these medications in T1D has not yet been proposed.